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The high prevalence of contaminated cell cultures suggests that viral contaminations might be distributed among cultures.
We investigated more than 460 primate cell lines for Epstein-Barr (EBV), hepatitis B (HBV), hepatitis C (HCV), human
immunodeﬁciency virus type 1 (HIV-1), human T-cell leukemia/lymphoma virus I and II (HTLV-I/-II), and squirrel monkey
retrovirus (SMRV) infections for risk assessment. None of the cell lines were infected with HCV, HIV-1, or HTLV-I/-II. However,
one cell line displayed reverse transcriptase activity. Thirty-nine cell lines harbored EBV DNA sequences. Studies on the lytic phase
of EBV revealed that ﬁve cell lines produce EBV particles and six further cell lines produced EBV upon stimulation. One cell
line contained an integrated HBV genome fragment but showed no virus production. Six cell lines were SMRV-infected. Newly
established cell lines should be tested for EBV infections to detect B-lymphoblastoid cell lines (B-LCL). B-LCLs established with
EBV from cell line B95-8 should be tested for SMRV infections.
1.Introduction
Human primary cell cultures and cell lines have become
fundamental tools for basic research in numerous life science
f a c u l t i e sa sw e l la sf o rt h ep r o d u c t i o no fb i o a c t i v er e a g e n t s
in biomedicine and biotechnology. They are already used
for several decades and frozen cell cultures or blood and
tissue samples obtained many years ago can be found
in numerous laboratories. As known from experience in
the transfusion and transplantation medicine, human cells
can harbor a number of diﬀerent human pathogens and
conveyed a potential risk for the recipients to become
infected before extensive screenings of the material were
accomplished. In particular, human pathogenic viruses like
human immunodeﬁciency virus type 1 (HIV-1), human T-
cell leukemia/lymphoma virus type I and II (HTLV-I and
-II), and hepatitis viruses, for example, hepatitis B virus
(HBV) and hepatitis C virus (HCV), are found in human
donor and patient material [1]. Cell lines were usually
established from patient material which might similarly be
infected with those viruses or perhaps with viruses linked
to speciﬁc tumors, for example, human herpes virus type
8 (HHV-8) or novel types of papilloma viruses [2]. A
considerable percentage of cell lines was established before
viral contaminations had been routinely assayed or even
before those viruses had been discovered. Additionally, the
risk of emerging pathogens has to be kept under constant
review [3].
Indeed, some cell lines are known to harbor human
pathogenic viruses, among them the well-known and widely
distributed HeLa cell line which contains the human papil-
loma virus integrated into its genome [4]. Besides the infec-
tion of the primary material which may be traced back to the
donor,contaminationsofcellculturescanalsobeintroduced
secondarily by laboratory personnel or from other infected
cells when handled simultaneously. Such means of infection
are much more likely, as similar problems were shown for
mycoplasma contaminations (an incidence of ca. 25% has
been reported) and cross contaminations of cell cultures (ca.
15%) [5]. This type of infection with transmissible viruses
might be true for the contamination with squirrel monkey
retrovirus (SMRV), which was detected in some human and2 Journal of Biomedicine and Biotechnology
animal cell lines; sequences of the virus were shown to be
present in interferon-α preparations produced by the human
Burkitt lymphoma cell line NAMALWA [6, 7].
Human and animal cells themselves represent no
increased risk during routine cell culture. But an infection
of the cells with human pathogenic viruses or bacteria
increases the potential risk of a cell culture. Although the
probability of the unintentional establishment of a cell line
which is infected with a high-risk virus is extremely low,
primary cells and cell cultures of unknown origin should
be regarded as potentially harmful and are categorized as
risk group 2, at least until the infection status of the donor
or the cells is clearly determined. Whereas some viruses
can be easily propagated in continuous cell lines (e.g.,
human retroviruses), propagation of other viruses depends
on the microenvironment or maturation of the otherwise
permissive cells. Additionally, some viruses exhibit a latent
or cryptic infection cycle, during which no active viruses
are produced (e.g., Epstein-Barr virus (EBV), proviruses of
retroviruses). However, the latent status can be switched to
the productive lytic cycle by certain inducers, or constantly
low replication rates can be found [8].
In this report, we describe the use of polymerase chain
reaction (PCR) assays, enzyme-linked immunosorbent assay
(ELISA), Southern and Western blotting for the detection
of latent and active forms of the human pathogenic viruses
( E B V ,H B V ,H C V ,H I V - 1 ,H T L V - Ia n d- I I ) ,S M R V ,a n d
retroviruses in general in a large panel of continuous primate
cell lines to determine the potential risk for handling these
cell lines. Regarding EBV, the inducibility of the lytic cycle
was investigated by treatment of the latently infected cell
lines with the phorbol ester 12-O-tetradecanoylphorbol-13-
acetate (TPA) and sodium butyrate (Na-butyrate).
2.MaterialsandMethods
2.1. Culture of Cell Lines. The continuous cell lines were
provided for accessioning to the cell lines bank by the
original or secondary investigators [9]. Cell lines were grown
at 37
◦C in a humidiﬁed atmosphere of air containing
5% CO2. The basic growth media (Invitrogen, Karlsruhe,
Germany) were supplemented with 10%–20% fetal bovine
serum (FBS) (Sigma, Deisenhofen, Germany). For growth
factor-dependent cell lines, speciﬁc growth factors or con-
ditioned media containing growth factors were added. No
antibiotics were added to the cultures. All cell lines were
free of mycoplasma and other bacterial, yeast, and fungi
contaminationsastestedbyPCRandmicrobiologicalgrowth
assays [10]. The authenticity of the cell lines was determined
by DNA typing [11]. For the induction of the lytic cycle of
EBV infection, PCR-positive cell lines were treated for 3 days
with 10
−7 M TPA (Sigma) and 3mM Na-butyrate (Sigma).
2.2. Western Blotting Analysis. At o t a lo f1× 106 cells were
pelleted and washed with ice-cold phosphate buﬀered saline
(PBS), resuspended in 30μL ice-cold protease inhibitor
buﬀer containing 0.1M NaCl, 10mM Tris-HCl, pH 7.5,
1mM EDTA, 1μg/mL aprotinin, and 100μg/mL phenyl-
methylsulfonyl ﬂuoride and boiled for 10 minutes after
addition of 30μL2× SDS gel-loading buﬀer containing
125mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerol 2% β-
mercaptoethanol, and 0.1% bromophenol blue. Proteins
were separated on 10% SDS-PAGE. Blotting and staining
conditions were as described previously [12]. BZLF1 protein
was detected using the mouse anti-ZEBRA antibody (Dako-
Cytomation, Hamburg, Germany) diluted 1:100 in PBS and
5% FBS.
2.3. RT-ELISA. Most of the cell lines were analyzed for gen-
eral infections with retroviruses applying an ELISA. Brieﬂy,
using 5mL cell free culture supernatant, retrovirus particles
were concentrated by ultracentrifugation at 100,000×go r
by polyethylene glycol precipitation and subsequent cen-
trifugation at 800×g. The pellets were analyzed applying
the Reverse Transcriptase Assay, nonradioactive, from Roche
(Mannheim, Germany). In this assay, digoxigenin- and
biotin-labeled desoxyuridine-triphosphates areincorporated
in the presence of viral reverse transcriptase during the
synthesis of a DNA strand along a synthetic target of
single-stranded DNA molecules. The newly synthesized
DNA is trapped on streptavidin-coated microtiter plates
and subsequently detected immunologically by binding of
peroxidase-labeledantidigoxigeninantibodiesandvisualized
by color development and ﬁnally quantiﬁed by measuring
the absorbance with an ELISA reader [13]. Two diﬀerent
buﬀers were used to detect Mg2+-dependent RT as well as
Mn2+-dependent RT of mammalian C-type retroviruses.
2.4. In Situ Lysing Gel Analysis. Episomal and linear forms of
EBVDNAweredistinguishedbyhorizontalgelelectrophore-
sis according to Gardella et al. [14]. After electrophoresis, the
separated DNA was blotted onto nylon ﬁlters (see Southern
blotanalysis)andtheDNAwashybridizedwitha 32Plabeled
ca. 37kb DNA fragment of the 5 -region of EBV (cM-Sal A)
[15].
2.5. Southern Blot Analysis. Genomic DNA of cell lines or
DNA from EBV was extracted and puriﬁed using the PCR
High Pure DNA kit from Roche. Fifteen μgo fg e n o m i c
DNA or EBV DNA from 24mL supernatant of the B95-8
cell line were digested with 150U XhoIr e s t r i c t i o ne n z y m e
over night. After electrophoresis, the separated DNA was
blotted onto a nylon membrane and hybridized with various
radioactively labeled cosmid probes from the EBV genome
[15]asdescribedearlier[16].Probesforthe5 -and3  -region
of the linear EBV genome were prepared by PCR. An 894bp
fragment of the 5 -region was ampliﬁed using the forward
primer F-EBV1 (5 -AGG CAT TTA CGG TTA GTG TG-
3 ) and the reverse primer R-EBV1 (5 -CGG TCA GGATA-
G CAA GAA T-3 ). PCR was carried out with 35 cycles of
30seconds at 95
◦C, 30 seconds at 52
◦C, and 1 minute at
72
◦C with hotstart Taq (TaKaRa, Lonza, Verviers, Belgium).
A 619bp fragment of the 3 -region of the linear EBV
genome was ampliﬁed using the forward primer F-EBV2 (5 -
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primer R-EBV2 (5 -CAA GCC GCA GCG ACT TTC-3 ).
PCR was carried out with 35 cycles of 30 seconds at 95
◦C,
30 seconds at 59
◦C, and 1 minute at 72
◦C with hotstart
Taq. The PCR fragments were isolated from the gels and
cloned into pGEM-T-easy vectors (Invitrogen). Aliquots of
the clear lysates were labeled with 32P by nick translation
and hybridized to the Southern blots. Signals were detected
with a phosphor imager (Molecular Dynamics, Sunnyvale,
CA, USA).
2.6. PCR Assays. PCR or RT-PCR was applied for the
detection of speciﬁc DNA or RNA sequences of the human
pathogenic viruses EBV, HBV, HCV, HHV-8, HIV-1, HTLV-
I and -II, and SMRV. DNA sequences integrated into the
cellular genome (proviruses) and episomal DNA of EBV
and HHV-8 were detected using the PCR ampliﬁcation
method. DNA from cell lines was isolated applying the High
Pure PCR Template Preparation kit from Roche. Speciﬁc
oligonucleotide pairs from the gag region of HIV-1 (SK 38
and SK 39) [17], the pol region of HLTV-I/-II (SK 110 and
SK 111) [18], the gag and env region of SMRV (F-SMRV-
env, R-SMRV-env and F-SMRV-gag, R-SMRV-gag), from the
EB2 (BMLF1) gene of EBV (TC 70 and TC 72) [19], and
the putative minor capsid protein gene of HHV-8 (F- and
R-HHV-8) [20] were used with the appropriate annealing
temperatures in the PCR reaction (Table 1). The hot start
PCR was either carried out by denaturing the reaction-mix
which contains no Taq-polymerase for 7 minutes at 94
◦C,
subsequently adding the Taq-polymerase mix (1U/reaction)
during the following cycle step at 72
◦Cf o r3m i n u t e s ,
annealing for 2 minutes at the appropriate temperature,
and ampliﬁcation at 72
◦C for 10 minutes, or by using
hotstart Taq-polymerase with initial cycles according to the
manufacturer’s recommendations. After the initial cycle, 35
cycles were run at 95
◦C for 30 seconds, template speciﬁc
annealingtemperaturefor30seconds,and72
◦Cfor1minute
plus 2 seconds extension for each cycle. The ampliﬁed
products were identiﬁed by agarose gel electrophoresis and
visualized by ethidium bromide intercalation.
T h ea c t i v ef o r mo fH B Vw a st e s t e db yo r g a n i ce x t r a c t i o n
of DNA from 5mL supernatant of the cell lines after
enrichment of particles by ultracentrifugation (15 minutes
at 100,000 × g). PCR was carried out using forward
and reverse primers from the conserved region of the
precore/core protein gene to detect the diﬀerent subtypes of
HBV (Table 1). For the detection of the hepatitis B surface
antigen coding region in cell line HEP-3B, a second primer
pair was applied, consisting of the forward primer F-HBV-3
(5 -CAA GAT TCC TAT GGG AGT GGG CCT-3 )a n d
R-HBV-4 (5 -CTC TGC CGA TCC ATA CTG CGG AAC-
3 ).
For HCV detection, total RNA was isolated from cells
by organic extraction with Trizol Reagent (Invitrogen)
as described by the manufacturer. Five μg were reverse
transcribed using random primers and SuperScript reverse
transcriptase according to the recommendations of the
manufacturer (Invitrogen). The equivalent of 1μgR N Aw a s
used for RT-PCR. The ampliﬁcation was carried applying
primers from the 5  untranslated region (5 -UTR) of HCV
[21]( Table 1).
In all PCR runs appropriate positive, negative, and
internal controls were integrated in parallel reactions. As
positive control for HIV, a plasmid containing the gag and
pol region of HIV-1 was used. This was kindly provided by
Dr. H. Hauser (Helmholtz Center for Infection Research,
Braunschweig, Germany). As positive control for HTLV, we
applied genomic DNA from the human T leukemia cell line
MT-1. This cell line is infected with HTLV-I [22]. Regarding
EBV and HHV-8, genomic DNA of the cell lines RAJI and
CRO-AP2 were used as positive control DNA, respectively
[20]. Active HBV reference plasma (subtypes ad and ay)
were applied to establish the PCR procedure and used as
positive controls. The plasma samples were obtained from
the German National Reference Center for Virus Hepatitis
(G¨ ottingen, Germany). A plasmid containing the HCV 5 -
UTR was kindly provided by Professor Dr. M. Roggendorf
from the National Reference Center for Hepatitis C (Essen,
Germany).
Except for HHV-8 and SMRV, internal control DNA
for each of the PCR assays was constructed starting from
the PCR products of the positive control DNA. In general,
DNA fragments were cloned into the PCR products to retain
the target sequences of the respective primer pairs, but to
obtain a PCR product which is signiﬁcantly longer than the
original PCR product of the wild type sequence. For HIV
and HTLV, a 250bp HCV positive control PCR fragment was
inserted into the HIV and HTLV fragments, according to the
“gene splicing by overlap extension” method described by
Telenti et al. [23].
For HBV, the PCR product of the positive control
reaction was ligated into the pGEM-T vector and a 445bp
fragment was excised from the insert employing the restric-
tion enzyme BglII. A 788bp DNA fragment was isolated
after digestion of the pGEM vector applying MboI. Both
restriction enzymes produce the same sticky end sequences.
Thus, the shortened and linearized vector containing the
HBV PCR product ends can be ligated with the pGEM
restriction fragment, transformed into E. coli, and the
resulting plasmid can be used as internal control DNA for
HBV. The fragment is 343bp longer than the wild type
sequence. A similar strategy was applied for HCV. The PCR
product from the positive control DNA was ligated into the
pGEM-T vector and a 187bp fragment was excised using the
restriction enzyme SmaI. pHSSE-1 was digested with RsaI
and a 379bp fragment was extracted from the gel. Blunt-end
ligation of the two DNA sequences and transformation into
E.coliproducedaplasmidcontainingaDNAsequencewhich
can be ampliﬁed with the HCV primer and is 192bp longer
than the wild type DNA.
2.7. Interphase FISH. O n em i l l i o nc e l l sw e r ec e n t r i f u g e da t
200×g for 5 minutes. The pellet was washed with 5mL
PBS, centrifuged again at 200×g for 5 minutes, and the cells
were resuspended in 0.5mL PBS. One hundred μl of the cell
suspension were centrifuged onto acid washed slides using
a cytospin centrifuge. The slides were air-dried and the cells4 Journal of Biomedicine and Biotechnology
Table 1: Primer sequences and PCR product sizes of wild type and internal control DNAs.
ABL:
F-ABL-A2: 5 -TGA CTT TGA GCC TCA GGG TCT GAG TGA AGC
C-3 
R-ABL-A3: 5 -CCA TTT TTG GTT TGG GCT TCA CAC CAT TCC-3 
Annealing temperature: 70
◦C
Reference sequence (mRNA): GenBank:NM 007313
Reference sequence (genomic DNA): GenBank:U07563
Nucleotide position (mRNA): 159–374
Nucleotide position (genomic DNA): 49914–50692
RT-PCR product: 216 bp
PCR product: 779bp
Taq polymerase: TaKaRa ExTaq HS (Lonza)
EBV:
F-EBV (TC-70): 5 -CTT GGA GAC AGG CTT AAC CAG ACT CA-3 
R-EBV (TC-72): 5 -CCA TGG CTG CAC CGA TGA AAG TTA T-3 
Annealing temperature: 60
◦C
Reference sequence: GenBank: V01555 Nucleotide positions: 83520–83784
PCR product (wild type): 265bp PCR product (internal control): 445 bp
Taq polymerase: TaKaRa Taq HS (Lonza)
HBV:
F-HEPB: 5 -AAG CTG TGC CTT GGG TGG CTT-3 
R-HEPB: 5 -CGA GAT TGA GAT CTT CTG CGA C-3 
Annealing temperature: 55
◦C
Reference sequence: GenBank: NC 003977 Nucleotide positions: 1874–2436
PCR product (wild type): 563bp PCR product (internal control): 906bp
Taq polymerase: BioTherm Taq polymerase (Gene Craft, L¨ udinghausen, Germany)
HCV:
F-HCV: 5 -GCC ATG GCG TTA GTA TGA GT-3 
R-HCV: 5 -RTG CAC GGT CTA CGA GAC CT-3 
Annealing temperature: 55
◦C
Reference sequence: GenBank: NC 004102 Nucleotide positions: 82–340
PCR product (wild type): 259bp PCR product (internal control): 452bp
Taq polymerase: TaKaRa ExTaq HS (Lonza)
HHV-8:
F-HHV-8: 5 -AGC CGA AAG GAT TCC ACC AT-3 
R-HHV-8: 5 -TCC GTG TTG TCT ACG TCC AG-3 
Annealing temperature: 56
◦C
Reference sequence: GenBank: NC 009333 Nucleotide positions: 47386–47618
PCR product: 232bp
Taq polymerase: TaKaRa ExTaq HS (Lonza)
HIV-1:
F-HIV (SK38): 5 -ATA ATC CAC CTA TCC CAG TAG GAG AAA T-3 
R-HIV (SK39): 5 -TTT GGT CCT TGT CTT ATG TCC AGA ATG C-3 
Annealing temperature: 50
◦C
Reference sequence: GenBank: NC 001802 Nucleotide positions: 1090–1204
PCR product (wild type): 114bp PCR product (internal control): 403bp
Taq polymerase: TaKaRa Taq HS (Lonza)Journal of Biomedicine and Biotechnology 5
Table 1: Continued.
HTLV-I/-II:
F-HTLV (SK110): 5 -CCC TAC AAT CCA ACC AGC TCM G-3 
5 -CCT TAC AAT CCA ACC AGC TCA G-3 
5 -CCA TAC AAC CCC ACC AGC TCA G-3 
R-HTLV (SK111): 5 -GTG RTG GAT TTG CCA TCG GGT T-3 
5 -GTG GTG AAG CTG CCA TCG GGT T-3 
Annealing temperature: 60
◦C
Reference sequence: GenBank: NC 001436 Nucleotide positions: 4384–4569
PCR product (wild type): 186bp PCR product (internal control): 405bp
Taq polymerase: TaKaRa Taq HS (Lonza)
SMRV:
F-SMRV-env: 5 -GGC GGA CCC CAA GAT GCT GTG-3 
R-SMRV-env: 5 -TGG GCT AGG CTG GGG TTG GAG ATA-3 
Annealing temperature: 67
◦C
Reference sequence: GenBank: M23385 Nucleotide positions: 6857–7053
PCR product: 197bp
Taq polymerase: TaKaRa Ex Taq HS (Lonza)
F-SMRV-gag: 5 -TCA GAG CCC ACC GAG CCT ACC TAC-3 
R-SMRV-gag: 5 -CAG CGC AGC ACG AGA CAA GAA AA-3 
Annealing temperature: 67
◦C
Reference sequence: GenBank: M23385 Nucleotide positions: 1737–1922
PCR product: 186bp
Taq polymerase: TaKaRa Taq HS (Lonza)
were ﬁxed in a mixture of methanol and acetic acid (3:1)
for 30 minutes in the cold. The ﬁxation step was repeated
twice. Then the slides were air-dried for ca. 10 minutes.
The samples were dehydrated with an ethanol series (70%,
70%, 90%, 90%, and 100%, each for 2 minutes). The slides
were again air-dried for 10 minutes and processed further or
stored at −20
◦C with desiccant.
The EBV cosmid DNA was labeled with Cy3 or Spec-
trum Green (Vysis, Stuttgart, Germany) by nick-translation
(Roche) according to the manufacturer’s protocols. Ca.
40ng of the labeled probe was added to 1μgo fh u m a n
Cot DNA (Roche) and ethanol precipitated. The pellet was
resuspended in 10μl Hybrizol VII (Qbiogene, Heidelberg,
Germany), placed on the slide, covered with a cover slip, and
sealed with rubber cement. The preparations were denatured
at 80
◦C on a heating plate and the subsequent hybridization
was carried out at 37
◦C over night.
Slides were washed in 2 × SSC at room temperature
for 1 minute, 3 times in 50% formamide/50% 2 × SSC
at 40
◦Cf o r3m i n u t e s ,3t i m e si n2× SSC at 40
◦Cf o r2
minutes, and 5 minutes at room temperature in 4 × SSC.
Slides were mounted with Vecta-Shield containing 1μg/mL
counterstain 1 (Hoechst, Frankfurt, Germany) and evaluated
with a ﬂuorescence microscope.
3. Results andDiscussion
3.1. Detection of EBV. EBV became the prime example
of a human tumor virus that is etiologically linked to a
diverse range of malignancies. EBV has been associated
with a variety of lymphoid and epithelial malignancies,
such as Burkitt lymphoma, Hodgkin lymphoma, T-cell
lymphomas, AIDS-related lymphomas, nasopharyngeal car-
cinoma, and lymphoepithelioma-like carcinomas of several
organs including stomach, salivary glands, thymus, and
lung [24]. Additionally, EBV has the unique capability to
transform and immortalize resting B cells into permanently
growing B-lymphoblastoid cell lines (B-LCL). As EBV is
ubiquitously distributed in all human populations and more
than 90% of the individuals are infected, the detection of
EBV is a priori not a matter of safety. However, for quality
control reasons and moreover due to the potential of EBV to
transform B cells, cell banks should routinely determine the
EBV infection status of cell lines. Not every cell line derived
from a tumor patient is necessarily a tumor cell line as
nonmalignant cells which are independent of the tumor cells
may sometimes be immortalized as well. In a leukemic con-
text, such cell lines are usually normal B-cells which become
immortalized through incorporation of the EBV genome.
There are several hematopoietic diseases from which it is
notoriously diﬃcult to establish cell lines, in particular the
mature B-cell malignancies such as chronic lymphocytic
leukemia, hairy cell leukemia, plasma cell leukemia (PCL),
multiple myeloma, and Hodgkin lymphoma. While there
are number of bona ﬁde myeloma-, PCL-, and Hodgkin
lymphoma-derived cell lines, various cell lines which are
in reality EBV+ B-LCLs have been described and are still
being used as model systems for these diseases. Experimental6 Journal of Biomedicine and Biotechnology
results from such misclassiﬁed cell lines might easily lead to
false conclusions regarding the investigated tumor type.
AlthoughthecontaminationwithEBVisnotdetrimental
to the cell culture, the eﬀect of the contamination can be
manifold. For example, the gene regulation of the cells can
be inﬂuenced by transcription factors or altered methylation
patterns, and central signal transduction pathways might
be activated or inhibited by viral products (e.g., NF-κB,
interferons) and might alter the physiology of the cells
signiﬁcantly.
We also investigated the presence of EBV infections in
nonhematopoietic cell lines to determine whether some of
thecarcinomacelllinesoftheabovementionedtissuesmight
also be linked to EBV infections. In order to inhibit spread of
theinfectionsamongcellculturesandfortheclassiﬁcationof
thecelllinesintoriskgroups,itisimportanttoknowwhether
the infection is latent and no active viruses are produced or
whether EBV particles are produced during the lytic phase of
infection. In some cell lines the lytic phase of EBV infection
can be induced, depending on the culture conditions. The
possibility of induction of the release of active viruses was
investigated by the treatment of the cells with TPA and
Na-butyrate, because it is also relevant for the risk group
classiﬁcation of the cell lines.
The general infection status of cell lines with EBV was
analyzed by PCR. This method detects linear genomes of
the active EBV particles as well as EBV genomes integrated
into the eukaryotic chromosomes and nonintegrated EBV
episomes. The analyses revealed that 39 out of 465 primate
cell lines contain sequences of the EBV genome (see Tables 2
and 3). Figure 1 shows a representative gel after performing
EBV-PCR.AllPCRpositivehumancelllineswereestablished
from B-lineage leukemia/lymphoma cells, natural killer cells,
or are EBV transformed B-lymphoblastoid cells. No cell lines
originating from other tissues were found to be EBV+.T o
demonstrate the integrity and the sensitivity of the PCR runs
each sample was assayed in duplicate, one reaction without
an internal control, and one reaction was spiked with the
internal control DNA in a dilution that was close to the
detection limit of the PCR assay (Figure 1).
A number of cell lines were examined for EBV infection
by the originators of the cell lines or later on by other
investigators. In the majority of cases the EBV status of the
cell lines was determined immunologically by the detection
of EBV nuclear antigen (EBNA), early antigen (EA), and/or
viral capsid antigen (VCA). Concordance of our PCR results
with data for protein expression given in the literature
was found in nine cell lines (ARH-77, BONNA-1, HC-
1, JIYOYE, L-591, MEC-1, MEC-2, RAJI, and YT) [9, 25,
26]. The DOHH-2 cell line was originally described as
EBV negative but was later on found to be EBV positive
in EBNA immunoﬂuorescence staining and PCR [27, 28].
In three cell lines (CRO-AP2, CRO-AP5, and HC-1) EBV
sequences were demonstrated by Southern blotting [29–
31] and four cell lines were described to be established by
immortalization with EBV particles from supernatant of
the B95-8 cell line (EHEB, JVM-13, JVM-2, and JVM-3)
[32, 33]. The monkey cell line B95-8 is known to produce
infectious EBV particles [34]. In contrast to our PCR results,
the cell lines CI-1, NK-92, and TMM were speciﬁed as EBV
negative as examined by EBNA and PCR assays [35–37].
Our PCR results were veriﬁed by FISH, in situ lysing gel
analysis, Southern and Western blotting as described below
and showed in at least two additional assays that all those cell
lines are clearly EBV-positive (see Table 2).
The CI-1, DOHH-2, and TMM cell lines were positive
in our PCR assay but showed weak or few signals in in situ
lysing gel analysis and FISH (see below). This indicates that
theEBVloadofthecellsisverylowandthattheexpressionof
EBNAproteininthesethreecelllineswasbelowthedetection
limit of the immunological assays. Thus, PCR is a convenient
and reliable assay to detect EBV infections in cell cultures,
provided that the appropriate control reactions including
internal DNA controls are performed to avoid false positive
and false negative results.
The activation of the lytic phase of the virus is usually
closely connected with the production of infectious virus
particles in the cells. The permissivity of a cell line relating to
EBV is important to determine legally the risk group of the
cell line as only cell cultures producing active viruses should
represent an elevated risk. To identify the lytic phase of the
EBV infections, we analyzed the expression of the ZEBRA
protein (Bam HI Z Epstein-Barr replication activator) [38]
by Western blotting applying an anti-ZEBRA monoclonal
antibody. ZEBRA is the product of the BZLF1 gene and
is a transcriptional activator that mediates a genetic switch
between the latent and lytic states of EBV. ZEBRA binds to
the promoters of genes involved in lytic DNA replication
activating their transcription [39]. Thus, phorbol esters and
Na-butyrate are among the most reproducible and most
broadly applicable inducers of the lytic cycle of EBV [8].
However, not all latently infected lymphoblast cell lines can
be induced by TPA and only a minority of the cells within a
culture is inducible at all. In some human B-LCL about 10%
of the cells can be induced to permit lytic virus replication,
whereasinafewothers20%–50% inducedcellscanbefound
[8]. Marmoset lymphoblasts seem to be more inducible, for
example, the B95-8 cell line [40]. For this reason we used the
B95-8 cell line as positive control to determine the eﬃciency
of the induction with TPA/Na-butyrate.
AllEBVPCR+celllineswereincubatedwithandwithout
10
−7 M TPA for 3 days and analyzed for ZEBRA expression.
As shown in Table 2, ﬁve unstimulated cell lines exhibited
a ZEBRA speciﬁc band of approximately 40kDa (B95-8,
BD-215, L-591, NC-NC, and YT). The expression of the
protein was weak in all ﬁve cell lines but increased after
TPA/Na-butyrate stimulation. B95-8 and BD-215 increased
strongly, whereas L-591 and YT increased only moderately.
Six additional cell lines which showed no expression in the
absence of TPA/Na-butyrate produced the ZEBRA protein in
various amounts after induction of the lytic phase with TPA
(EB-1, GRANTA-519, HC-1, IM-9, JIYOYE, and VAL). All
other cell lines tested (n = 28) did not express the BZLF1
gene product even after stimulation with TPA/Na-butyrate.
Figure 2 shows a representative Western blot with positive
and negative cell lines. Lieberman et al. [41] showed that the
ZEBRA protein is induced by TPA in RAJI cells. This was not
conﬁrmed in our screening for ZEBRA expression. RAJI isJournal of Biomedicine and Biotechnology 7
Table 2: EBV-PCR+ cell lines, BZLF1 expression detected by Western blotting, diﬀerentiation of episomal and linear EBV-DNA, EBV
sequence pattern detected by Southern blotting, and episomal load determined by FISH.
Cell line Cell type PCRa BZLF1 expr.a In situ lysing gelb
Southern blotc FISHd
untr. TPA episomal linear
ARH-77 B-LCL + −− (+) − ++
B95-8 marmoset monkey lymphocytes + + + ++ +++ + +++
BD-215 B-LCL + + + + + + ++
BONNA-12 hairy cell leukemia + −− ++ + + ++ (h)
CI-1 B cell lymphoma + −− + − n.d. +
COLO-720L B-LCL + −− ++ + + +
CRO-AP2 B cell lymphoma + −− (+) − ++ +
CRO-AP5 B cell lymphoma + −− (+) − ++ +
DAUDI Burkitt lymphoma + −− +++ + + ++ (h)
DOHH-2 B cell lymphoma + −− − − − +( f)
EB-1 Burkitt lymphoma + − ++ ++ + + ( h )
EHEB chronic B cell leukemia + −− +( + ) + n . d .
GRANTA-519 B cell lymphoma + − ++ + + ++ + +
HC-1 hairy cell leukemia + − + ++ (+) + ++++
IM-9 B-LCL + − + +++ − + ++++
JIYOYE Burkitt lymphoma + − + ++ ++ + +++
JVM-13 chronic B cell leukemia + −− ++ (2 bands) − + ++++
JVM-2 chronic B cell leukemia + −− + + + +++
JVM-3 chronic B cell leukemia + −− ++ + + ++
L-591 B-LCL + + + ++ ++ + +++
LCL-HO B-LCL + −− ++ (+) + +++
LCL-WEI B-LCL + −− ++ + + +
MEC-1 chronic B cell leukemia + −− ++ + + + ( h )
MEC-2 chronic B cell leukemia + −− + − ++ + ( h )
NAMALWA Burkitt lymphoma + −− − − (+) −
NAMALWA.CSN/70 Burkitt lymphoma + −− − − (+) −
NAMALWA.IPN/45 Burkitt lymphoma + −− − − (+) −
NAMALWA.KN2 Burkitt lymphoma + −− − − (+) −
NAMALWA.PNT Burkitt lymphoma + −− − − (+) −
NC-NC B-LCL + + + ++ ++ + +++
NK-92 natural killer lymphoma + −− ++ + +
OCI-LY-19 B cell lymphoma + −− − − − −
RAJI Burkitt lymphoma + −− +++ + + ++++
RO B-LCL + −− + − ++ +
SD-1 B-LCL + −− ++ + + +++
T2 human-human somatic cell hybrid + −− ++ + n.d. n.d.
TMM B-LCL + −− + (2 bands) (+) + +++
VAL B cell lymphoma + − + ++ (2 bands) + n.d. ++ (h)
YT T/natural killer cell leukemia + + + ++ +++ + +++
B-LCL: B-lymphoblastoid cell line; expr.: expression; n.d.: not determined; untr.: untreated.
a−: negative; +: positive.
b−: negative; (+): weakly positive; +: positive; ++: strongly positive; +++: very strongly positive.
c−: no bands visible; (+): very weak signals; +: clear bands visible.
d episomalloaddetectedbyFISH: −:noepisomes;+:lowload;++:load;+++:highload;++++:veryhighload;(h):heterogenousdistributionoftheepisomes
among the cells; (f): only a few cells containing episomes.8 Journal of Biomedicine and Biotechnology
a nonproducer cell line with at least two deletions in the EBV
genome and is defective for EBV DNA replication and late
gene expression [8]. On the other hand, Di Francesco et al.
[42] showed a weak induction of ZEBRA in Western blots
after treatment with TPA in combination with n-butyrate,
whereas further addition of cocain caused a high increase
in ZEBRA expression. These contradictory ﬁndings can be
explained by diﬀerent cell sources or cell passage histories.
However, importantly all studies demonstrated that ZEBRA
was not expressed during normal cell culture, and thus,
a production of viruses is very unlikely at nonstimulating
conditions.
The EBV genome can be present in the host cells as
covalently closed circles (episomes), as linear DNA of active
viruses, or integrated into the host genome. The episomes
are indicative for the latent infection status [8]. The EBV
infected cells can harbor 1–10 episomes in low load cells
or up to several hundred episomes in high load cells. EBV
producer cell lines contain also linear double stranded DNA
which is packaged into the virions. EBV genome integration
was described only for a small number of cell lines. For
example, the NAMALWA cell line and its subclones are
described to contain an integrated EBV genome [43]a n d
no episomes, whereas the RAJI cell line was reported to
contain both, chromosomally integrated EBV genomes as
well as episomes [44]. To distinguish between the linear
DNA of active viruses, episomal DNA of EBV-infected cell
cultures,andsolelyintegratedEBVgenomes,weperformeda
variation of a Southern blot analysis as described by Gardella
et al. [14].
The autoradiograms showed the episomal DNA as clear-
cut bands whereas the linear DNA usually formed distinct
bands within a smear of DNA (Figure 3). The episomal as
well as the linear DNA of the cell lines examined showed
diﬀerent migrations indicating diﬀerent EBV clones. Except
for the NAWALWA cell line and its subclones, DOHH-2,
and OCI-LY19, all EBV PCR positive cell lines showed at
least one band of episomal EBV genomes (Table 2). As no
denaturing conditions were applied in the in situ lysing
gels, diﬀerent sequences of the EBV strains can result in
diﬀerent conformations and mobilities of the episomes. The
cell lines COLO-720L, IM-9, JVM-13, LCL-HO, TMM, and
VAL displayed two episomal DNA bands. The intensities
of the episomal bands were almost identical only in the
cell line JVM-13. The existence of two EBV clones in one
cell line can be explained by three assumptions: (i) two
diﬀerent EBV clones simultaneously infected the cell which
led to the establishment of the cell line, (ii) the cell line was
established from two or more diﬀerent cells of the patient
harboringdiﬀerentEBVclones(oligoclonality),or(iii)single
and duplicated episomes are present in the nuclei of the cell
lines.
The NK-92 and TMM cell lines were described to be
EBV negative according to EBNA detection assay and PCR,
respectively [35, 37]. Both cell lines showed EBV speciﬁc
episomal DNA in the in situ lysing gels. This conﬁrmed
the results of the PCR assay as discussed above. Concerning
the NAMALWA cell lines, no episomal DNA bands were
expected, because the EBV DNA was described to be
100bp ladder
a
b
a
b
a
b
a
b
a
b
Internal control
Positive control
Water control
BV-173
EB-1
NAMALWA
RAJI
REH
Figure 1: PCR analysis of EBV status in cell lines. Shown is an
ethidium bromide-stained gel containing the reaction products
following PCR ampliﬁcation with the primers F-EBV and R-EBV
(see Table 1). Products of 265bp were obtained. Shown are various
examples of EBV-negative and EBV-positive cell lines. Two paired
PCR reactions were performed: one PCR reaction contained an
aliquot of the sample only (a) and the second reaction contained
the sample under study plus the control DNA as internal standard,
which results in an ampliﬁed product size of 445bp (b). The cell
cultures EB-1, NAMALWA, and RAJI are EBV-positive; the cell
cultures BV-173 and REH, both B-cell precursor leukemia cell lines,
are EBV-negative.
integrated into the eukaryotic genome [45]. Since no linear
DNA was detected, the integrated genome is not transcribed
in those cell lines. DOHH-2 and OCI-LY-19 might also
only contain integrated EBV genomes, but ﬂuorescence in
situ hybridization (FISH) indicates that the number of EBV
episomes in a cell culture is too low to be detected by in situ
lysing gels (see below).
The intensities of the episomal bands in the in situ
lysing gels were highly variable among the cell lines but were
constant for a given cell line, indicating that the EBV loads
are diﬀerent in the cell lines examined. The highest episomal
loads were found in the cell lines DAUDI, IM-9, L-591,
RAJI, and SD-1. Of these, only the L-591 cell line expressed
BZLF1 constitutively and IM-9 expressed the protein after
stimulation with TPA and Na-butyrate. The other BZLF1
expressing cell lines displayed a lower number of episomes.
This indicates that the lytic cycle induction is completely
indepentent from the number of episomes present in the
nuclei. High episomal loads were described for the cell line
DAUDI and RAJI, which carry 100–200 and 50–60 viral
copies per cell, respectively [23, 46]. Based on the intensities
oftheEBV-speciﬁcbandsintheautoradiogramsoftheinsitu
lysing gel assays, the numbers of episomes in IM-9 and SD-1
werecomparabletothoseofDAUDIorRAJI,respectively.All
other cell lines were low load cell lines with 1–10 EBV copies
percellcomparedtothehighloadcelllinesmentionedabove
(Figure 3).
In order to obtain more quantitative data on the EBV
load of the EBV+ cell lines, we performed single cell analysesJournal of Biomedicine and Biotechnology 9
Table 3 :L i s to fc e l ll i n e st e s t e df o rR Ta c t i v i t yb yE L I S A ,a n df o rt h ep r e s e n c eo fE B V ,H B V ,H C V ,H I V - 1 ,H T L V - I / - I I ,a n dS M R V .
C e l l l i n e Z e l l t y p R T - E L I S AH C VE B VH B VH I VH T L VS M R V
22RV1 Prostate cancer −−−− − −
23132/87 Gastric adenocarcinoma −− − − − − −
293 Embryonal kidney −− − − − − −
293T Embryonal kidney −−−− − −
380 Pre B cell leukemia −− − − − − −
42-MG-BA Glioma −− − − − − −
5637 Urinary bladder carcinoma −− − − − − −
639-V Urinary bladder carcinoma −− − − − −
647-V Urinary bladder carcinoma −− − − − − −
697 Pre B cell leukemia −− − − − − −
8305C Thyroid carcinoma −− − − − − −
8505C Thyroid carcinoma −− − − − − −
8-MG-BA Glioma −− − − − −
A-204 Rhabdomyosarcoma −− − − − − −
A-427 Lung carcinoma −− − − − − −
A-431 Epidermoid carcinoma −− − − − − −
A-498 Kidney carcinoma −− − − − − −
A-549 Lung carcinoma −− − − − − −
AC-1M32 Choriocarcinoma-trophoblast hybrid −−−− − −
AC-1M46 Choriocarcinoma-trophoblast hybrid −−−− − −
AC-1M59 Choriocarcinoma-trophoblast hybrid −−−− − −
AC-1M81 Choriocarcinoma-trophoblast hybrid −−−− − −
AC-1M88 Choriocarcinoma-trophoblast hybrid −−−− − −
ACH1P Choricarcinoma-trophoblast hybrid −−−− − −
ALL-SIL T cell leukemia −−−− − −
AML-193 Acute myeloid leukemia −−−− − −
AMO-1 Plasmocytoma −−−− − −
AN3-CA Endometrial adenocarcinoma −− − − − − −
AP-1060 Acute myeloid leukemia −−−− − −
ARH-77 Multiple myeloma − + −− − −
BC-3C Urinary bladder transitional cell carcinoma −−−− − −
B-CPAP Thyroid carcinoma −− − − − − −
BD-215 B lymphoblastoid cells −− + −− − −
BE-13 T cell leukemia −− − − − − −
BEN Lung carcinoma −−−− − −
BEN-MEN-1 Benign meningioma −−−− − −
BEWO Choriocarcinoma −−−− − −
BFTC-905 Urinary bladder transitional cell carcinoma −− − − − − −
BFTC-909 Kidney transitional cell carcinoma −− − − − − −
BHT-101 Thyroid carcinoma −− − − − − −
BHY Oral squamous carcinoma −− − − − − −
BL-2 Burkitt lymphoma −−−− − −
BL-41 Burkitt lymphoma −− − − − −
BL-70 Burkitt lymphoma −− − − − − −
BLUE-1 Burkitt lymphoma −−−− − −
BM-1604 Prostate carcinoma (derivative of DU-145) −− − − − − −
BONNA-12 Hairy cell leukemia −− + −− − −
BPH-1 Prostate benign hyperplasia −− − − − − −
BT-474 Breast ductal carcinoma −− − − − − −
BT-B Cervix carcinoma (subclone of HELA) −− − − − − −
BV-173 Pre B cell leukemia −− − − − − −
C-433 Ewing’s sarcoma −− − − − − −
CA-46 Burkitt lymphoma −− − − − − −
CACO-2 Colon adenocarcinoma −− − − − − −
CADO-ES1 Ewing’s sarcoma −− − − − − −10 Journal of Biomedicine and Biotechnology
Table 3: Continued.
Cell line Zelltyp RT-ELISA HCV EBV HBV HIV HTLV SMRV
CAKI-1 Kidney carcinoma −− − − − − −
CAKI-2 Kidney carcinoma −− − − − − −
CAL-120 Breast adenocarcinoma −−−− −
CAL-12T Non-small cell lung carcinoma −−−− − −
CAL-148 Breast adenocarcinoma −−−− − −
CAL-27 Tongue squamous cell carcinoma −−−− − −
CAL-29 Urinary bladder transitional cell carcinoma −−−− − −
CAL-33 Tongue squamous cell carcinoma −−−− − −
CAL-39 Vulva carcinoma −− − − − − −
CAL-51 Breast carcinoma −− − − − − −
CAL-54 Kidney carcinoma −− − − − − −
CAL-62 Thyroid anaplastic carcinoma −−−− − −
CAL-72 Osteosarcoma −−−− − −
CAL-78 Chondrosarcoma −−−− − −
CAL-85-1 Breast adenocarcinoma −−−− − −
CAPAN-1 Pancreas adenocarcinoma −− − − − − −
CAPAN-2 Pancreas adenocarcinoma −− − − − − −
CCRF-CEM T cell leukemia −− − − − − −
CGTH-W-1 Thyroid carcinoma −− − − − − −
CHP-126 Neuroblastoma −− − − − − −
CI-1 B cell lymphoma − + −− − −
CL-11 Colon carcinoma −−−− − −
CL-14 Colon carcinoma −−−− −
CL-34 Colon carcinoma −−−− − −
CL-40 Colon carcinoma −−−− − −
CMK Acute megakaryocytic leukemia −− − − − − −
CML-T1 T cell leukemia −− − − − − −
COLO-206F Colon carcinoma −− − − − − −
COLO-320 Colon adenocarcinoma −− − − − − −
COLO-677 Small cell lung carcinoma −− − − − − −
COLO-678 Colon carcinoma −− − − − −
COLO-679 Melanoma −− − − − − −
COLO-680N Esophagus squamous cell carcinoma −− − − − − −
COLO-699 Lung adenocarcinoma −− − − − − −
COLO-704 Ovary adenocarcinoma −− − − − − −
COLO-720L B lymphoblastoid cells −− + −− − −
COLO-783 Melanoma −− − − − − −
COLO-800 Melanoma −− − − − − −
COLO-818 Melanoma −− − − − − −
COLO-824 Breast carcinoma −− − − − − −
COLO-849 Melanoma −− − − − − −
CPC-N Small cell lung carcinoma −− − − − − −
CRO-AP2 B cell lymphoma −− + −− − −
CRO-AP3 B cell lymphoma −− − − − − −
CRO-AP5 B cell lymphoma −− + −− −
CRO-AP6 B cell lymphoma −−−− − −
CTV-1 T cell leukemia −− − − − − −
CX-1 Colon adenocarcinoma −− − − − − −
DAN-G Pancreas carcinoma −− − − − − −
DAUDI Burkitt lymphoma −− + −− − −
DB B cell lymphoma −−−− − −
DBTRG-05MG Glioblastoma −− − − − − −
DEL Malignant histiocytosis −− − − − − −
DERL-2 T cell lymphoma −−−− − −
DERL-7 T cell lymphoma −−−− − −Journal of Biomedicine and Biotechnology 11
Table 3: Continued.
C e l l l i n e Z e l l t y p R T - E L I S AH C VE B VH B VH I VH T L VS M R V
DG-75 Burkitt lymphoma −− − − − − −
DK-MG Glioblastoma −− − − − − −
DLD-1 Colon adenocarcinoma −− − − − − −
DM-3 Sarcomatoid mesothelioma −−−− − −
DND-41 T cell leukemia −−−− −
DOGKIT Burkitt lymphoma −−−− − −
DOGUM Burkitt lymphoma −−−− − −
DOHH-2 B cell lymphoma −− + −− − −
DU-145 Prostate carcinoma −− − − − − −
DU-4475 Breast carcinoma −− − − − − −
DV-90 Lung adenocarcinoma −− − − − − −
EB-1 Burkitt lymphoma −− + −− − −
ECV-304 Urinary bladder carcinoma (derivative of T-24) −− − − − − −
EFE-184 Endometrium carcinoma −− − − − − −
EFM-19 Breast carcinoma −− − − − − −
EFM-192A Breast carcinoma −− − − − − −
EFM-192B Breast carcinoma −− − − − − −
EFM-192C Breast carcinoma −− − − − − −
EFO-21 Ovary cystadenocarcinoma −− − − − − −
EFO-27 Ovary adenocarcinoma −− − − − − −
EGI-1 Bile duct carcinoma −− − − − − −
EHEB Chronic B cell leukemia −− + −− − −
EJM Multiple myeloma −−−− − −
EM-2 Chronic myeloid leukemia −− − − − − −
EM-3 Chronic myeloid leukemia −− − − − − −
EN Endometrial carcinoma −−−− − −
EOL-1 Eosinophilic leukemia −− − − − − −
EPLC-272H Lung carcinoma −− − − − − −
ESS-1 Endometrial stromal sarcoma −−−− − −
EVSA-T Breast carcinoma −− − − − − −
F-36P Acute myeloid leukemia −−−− − −
FKH-1 Acute myeloid leukemia −−−− − −
FU-OV-1 Ovarian cancer −−−− − −
GAMG Glioma −− − − − − −
GDM-1 Acute myelomonocytic leukemia −− − − − − −
GF-D8 Acute myeloid leukemia −−−− −
GIRARDI HEART C2 Cervix carcinoma (subclone of HELA) −− − − − − −
GIRARDI HEART C7 Cervix carcinoma (subclone of HELA) −− − − − − −
GMS-10 Glioblastoma −− − − − − −
GOS-3 Astrocytoma/oligodendroglioma −− − − − − −
GRANTA-519 B cell lymphoma −− + −− − −
GUMBUS Burkitt lymphoma −−−− − −
H-1184 Lung small cell carcinoma −−−− − −
H-1339 Lung small cell carcinoma −−−− − −
H-1963 Small cell lung carcinoma −−−− − −
H-209 Lung small cell carcinoma −−−− − −
H-2171 Small cell lung carcinoma −−−− − −
HAL-01 B cell precursor leukemia −−−− − −
HC-1 Hairy cell leukemia −− + −− − −
HCC-1143 Breast carcinoma −−−− − −
HCC-15 Non-small cell lung carcinoma −−−− − −
HCC-1599 Breast carcinoma −−−− − −
HCC-1937 Breast carcinoma −−−− − −
HCC-33 Lung small cell carcinoma −−−− − −
HCC-366 Lung squamous adenocarcinoma −−−− − −12 Journal of Biomedicine and Biotechnology
Table 3: Continued.
Cell line Zelltyp RT-ELISA HCV EBV HBV HIV HTLV SMRV
HCC-44 Non-small cell lung carcinoma −−−− − −
HCC-78 Non-small cell lung carcinoma −−−− − −
HCC-827 Non-small cell lung carcinoma −−−− − −
HCEC-12 Cornea endothelium −−−− − −
HCEC-B4G12 Cornea endothelium −−−− − −
HCEC-H9C1 Cornea endothelium −−−− − −
HCT-116 Colon carcinoma −−−− −
HCT-15 Colon adenocarcinoma −− − − − − −
HDLM-2 Hodgkin lymphoma −− − − − − −
HD-MY-Z Hodgkin lymphoma −− − − − − −
HDQ-P1 Breast carcinoma −−−− − −
HEL Erythroleukemia −− − − − − −
HELA Cervix carcinoma −− − − − − −
HELA-S3 Cervix carcinoma (subclone of HELA) −− − − − − −
HEP-3B Hepatocellular carcinoma −− − + −− −
HEP-G2 Hepatocellular carcinoma −− − − − −
HL-60 Acute myeloid leukemia −− − − − − −
HMC-1 Mast cell leukemia −−−− − −
HN Oral squamous carcinoma −− − − − − −
HNT-34 Acute myeloid leukemia −−−− − −
HPB-ALL T cell leukemia −−−− −
HSB-2 T cell leukemia −− − − − − −
HT B cell lymphoma −−−− − −
HT-1080 Fibrosarcoma −− − − − −
HT-1376 Bladder carcinoma −− − − − − −
HT-29 Colon adenocarcinoma −− − − − − −
HTC-C3 Thyroid carcinoma −−−− − −
HUP-T3 Pancreas carcinoma −− − − − −
HUP-T4 Pancreas carcinoma −− − − − − −
IGR-1 Melanoma −− − − − − −
IGR-37 Melanoma −− − − − − −
IGR-39 Melanoma −− − − − − −
IM-9 Multiple myeloma −− + −− − −
IMR-32 Neuroblastoma −− − − − − −
IPC-298 Melanoma −− − − − − −
JAR Choriocarcinoma −−−− − −
JEG-3 Choriocarcinoma −−−− − −
JEKO-1 B cell lymphoma −−−− − −
JIMT-1 Breast carcinoma −−−− − −
JIYOYE B cell lymphoma − + −− − −
JJN-3 Plasma cell leukemia −−−− − −
JK-1 Chronic myeloid leukemia −− − − − − −
JL-1 Epitheloid mesothelioma −−−− − −
JMSU-1 Urinary bladder carcinoma −−−− − −
JOSK-I Histiocytic lymphoma (derivative of U-937) −− − − − −
JOSK-M Histiocytic lymphoma (derivative of U-937) −− − − − − −
JURKAT T cell leukemia −− − − − − −
JURL-MK1 Chronic myeloid leukemia in blast crisis −−−− − −
JURL-MK2 Chronic myeloid leukemia in blast crisis −−−− − −
JVM-13 Chronic B cell leukemia −− + −− − −
JVM-2 Chronic B cell leukemia −− + −− − −
JVM-3 Chronic B cell leukemia −− + −− − −
K-562 Chronic myeloid leukemia −− − − − − −
KARPAS-1106P B cell lymphoma −−−− − −
KARPAS-231 B cell leukemia −−−− − −Journal of Biomedicine and Biotechnology 13
Table 3: Continued.
Cell line Zelltyp RT-ELISA HCV EBV HBV HIV HTLV SMRV
KARPAS-299 T cell lymphoma −− − − − −
KARPAS-422 B cell lymphoma −− − − − − −
KARPAS-45 T cell leukemia −− − − − − −
KARPAS-620 Plasma cell leukemia −−−− − −
KASUMI-1 Acute myeloid leukemia + −−−− − −
KASUMI-2 B cell precursor leukemia −−−− − −
KB Cervix carcinoma (subclone of HELA) −− − − − − −
KB-3-1 Cervix carcinoma (subclone of HELA) −− − − − − −
KB-V1 Cervix carcinoma (subclone of HELA) −− − − − − −
KCI-MOH1 Pancreatic adenocarcinoma −−−− − −
KCL-22 Chronic myeloid leukemia in blast crisis −−−− −
KE-37 T cell leukemia −− − − − − −
KELLY Neuroblastoma −− − − − − −
KG-1 Acute myeloid leukemia −− − − − − −
KG-1a Acute myeloid leukemia −− − − − − −
KM-H2 Hodgkin lymphoma −− − − − −
KMOE-2 Acute erythremia −− − − − − −
KMS-12-BM Myeloma −−−− − −
KMS-12-PE Multiple myeloma −−−− − −
KOPN-8 B cell precursor leukemia −−−− − −
KPL-1 Breast carcinoma −− − − − − −
KU-19-19 Urinary bladder carcinoma −− − − − − −
KU-812 Chronic myeloid leukemia in myeloid blast crisis −− − − − − −
KYO-1 Chronic myeloid leukemia in blast crisis −−−− − −
KYSE-140 Esophageal carcinoma −− − − − − −
KYSE-150 Esophageal carcinoma −− − − − − −
KYSE-180 Esophageal carcinoma −− − − − − −
KYSE-270 Esophageal carcinoma −− − − − − −
KYSE-30 Esophageal carcinoma −− − − − − −
KYSE-410 Esophageal carcinoma −− − − − − −
KYSE-450 Esophageal carcinoma −− − − − − −
KYSE-510 Esophageal carcinoma −− − − − − −
KYSE-520 Esophageal carcinoma −− − − − − −
KYSE-70 Esophageal carcinoma −− − − − − −
L-1236 Hodgkin lymphoma −−−− −
L-363 Plasma cell leukemia −− − − − − −
L-428 Hodgkin lymphoma −− − − − − −
L-540 Hodgkin lymphoma −− − − − − −
L-591 B lymphoblastoid cells − + −− − −
L-82 Anaplastic large cell lymphoma −−−− −
LAMA-84 Chronic myeloid leukemia −− − − − − −
LAMA-87 Chronic myeloid leukemia in blast crisis −− − − − − −
LCLC-103H Lung carcinoma −− − − − − −
LCLC-97TM1 Lung carcinoma −− − − − − −
LCL-HO B lymphoblastoid cells −− + −− − +
LCL-WEI B lymphoblastoid cells −− + −− − −
LN-405 Astrocytoma −− − − − − −
LNCAP Prostata carcinoma −− − − − − −
LOUCY T cell leukemia −− − − − − −
LOU-NH91 Lung carcinoma −− − − − − −
LOVO Colon adenocarcinoma −− − − − −
LP-1 Multiple myeloma −− − − − − −
LXF-289 Lung adenocarcinoma −− − − − − −
M-07e Acute megakaryoblastic leukemia −− − − − − −
MB-1 Anaplastic thyroid carcinoma −−−− − −14 Journal of Biomedicine and Biotechnology
Table 3: Continued.
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MC-116 B cell lymphoma −− − − − − −
MCF-7 Breast adenocarcinoma −− − − − − −
MDA-MB-453 Breast carcinoma −− − − − − −
ME-1 Acute myeloid leukemia −−−− − −
MEC-1 Chronik B cell leukemia − + −− − −
MEC-2 Chronic B cell leukemia − + −− − −
MEG-01 chronic myeloid leukemia in megakaryocytic blast crisis −− − − − − −
MEL-HO Melanoma −− − − − − −
MEL-JUSO Melanoma −− − − − − −
MFE-280 Endometrium carcinoma −− − − − − −
MFE-296 Endometrium carcinoma −− − − − − −
MFE-319 Endometrium carcinoma −− − − − − −
MFM-223 Breast carcinoma −− − − − − −
MHH-CALL-2 B cell precursor leukemia −− − − − − −
MHH-CALL-3 B cell precursor leukemia −− − − − − −
MHH-CALL-4 B cell precursor leukemia −− − − − − −
MHH-ES-1 Ewing’s osteosarcoma −− − − − − −
MHH-NB-11 Neuroblastoma −− − − − −
MHH-PREB-1 B cell lymphoma −− − − − − −
MKN-45 Gastric carcinoma −− − − − − −
ML-1 Follicular thyroid carcinoma −−−− − −
ML-2 Acute myelomonocytic leukemia −− − − − − −
MN-60 B cell lymphoma −− − − − − −
MOLM-13 Acute myeloid leukemia −−−− − −
MOLM-16 Acute myeloid leukemia −−−− − −
MOLM-20 Chronic myeloid leukemia −−−− − −
MOLM-6 Chronic myeloid leukemia in blast crisis −−−− −
MOLP-2 Multiple myeloma −−−− − −
MOLP-8 Multiple myeloma −−−− − −
MOLT-13 T cell leukemia −− − − − − −
MOLT-14 T cell leukemia −− − − − − −
MOLT-16 T cell leukemia −− − − − − −
MOLT-17 T cell leukemia −− − − − − −
MOLT-3 T cell leukemia −− − − − − −
MOLT-4 T cell leukemia −− − − − − −
MONO-MAC-1 Acute monocytic Leukemia −− − − − − −
MONO-MAC-6 Acute monocytic leukemia −− − − − − −
MOTN-1 T cell leukemia −−−− − −
MSTO-211H Lung carcinoma −− − − − − −
MT-3 Breast carcinoma −− − − − − −
MUTZ-2 Acute myeloid leukemia −− − − − − −
MUTZ-3 Acute myelomonocytic leukemia −− − − − − −
MUTZ-5 B cell precursor leukemia −− − − − − −
MV4-11 Acute monocytic leukemia −− − − − − −
NALM-1 Chronic myeloid leukemia in blast crisis −− − − − − −
NALM-19 B cell precursor leukemia −−−− − −
NALM-6 B cell precursor leukemia −− − − − − −
NAMALWA Burkitt lymphoma −− + −− − +
NAMALWA.CSN/70 Burkitt lymphoma −− + −− − +
NAMALWA.IPN/45 Burkitt lymphoma −− + −− − +
NAMALWA.KN2 Burkitt lymphoma −− + −− − +
NAMALWA.PNT Burkitt lymphoma −− + −− − +
NB-4 Acute promyelocytic leukemia −− − − − − −
NCI-H510A Small cell extra-pulmonary carcinoma −−−− − −
NCI-H82 Small cell lung carcinoma −−−− − −Journal of Biomedicine and Biotechnology 15
Table 3: Continued.
C e l l l i n e Z e l l t y p R T - E L I S AH C VE B VH B VH I VH T L VS M R V
NCI-H929 Multiple myeloma −− − − − − −
NC-NC B-lymphoblastoid cells −− + −− − −
NK-92 Natural killer cell lymphoma − + −− − −
NOMO-1 Acute myeloid leukemia −−−− − −
NTERA-2 human embryonal carcinoma (teratocarcinoma) −−−− − −
NU-DHL-1 B cell lymphoma −−−− − −
NU-DUL-1 B cell lymphoma −−−− − −
OCI-AML2 Acute myeloid leukemia −− − − − − −
OCI-AML3 Acute myeloid leukemia −−−− − −
OCI-AML5 Acute myeloid leukemia −− − − − − −
OCI-LY-19 B cell lymphoma − + −− − −
OCI-M1 Acute myeloid leukemia −−−− − −
OCI-M2 Acute myeloid leukemia −−−− −
ONCO-DG-1 Papillary thyroid carcinoma −−−− − −
OPM-2 Multiple myeloma −− − − − − −
P12-ICHIKAWA T cell leukemia −− − − − − −
PA-TU-8902 Pancreas adenocarcinoma −− − − − − −
PA-TU-8988S Pancreas adenocarcinoma −− − − − − −
PA-TU-8988T Pancreas adenocarcinoma −− − − − − −
PC-3 Prostate carcinoma −−−− − −
PEER T cell leukemia −− − − − − −
PF-382 T cell leukemia −− − − − − −
PL-21 Acute myeloid leukemia −−−− − −
PLB-985 Acute myeloid leukemia −− − − − − −
RAJI Burkitt lymphoma −− + −− − −
RAMOS Burkitt lymphoma −−−− − −
RCH-ACV B cell precursor leukemia −−−− − −
RC-K8 B cell lymphoma −−−− − −
RD-ES Ewing’s osteosarcoma −− − − − − −
REC-1 B cell lymphoma −−−− − −
REH Pre B cell leukemia −− − − − − −
RH-1 Rhabdomyosarcoma −−−− − −
RH-18 Rhabdomyosarcoma −−−− − −
RH-30 Rhabdomyosarcoma −−−− − −
RH-41 Rhabdomyosarcoma −−−− − −
RI-1 B cell lymphoma −−−− − −
RL B cell lymphoma −−−− − −
RO B lymphoblastoid cell line − + −− − −
ROS-50 B cell leukemia −−−− −
RPMI-2650 Nasal septum squamous carcinoma −− − − − − −
RPMI-7951 Melanoma −− − − − − −
RPMI-8226 Multiple myeloma −− − − − − −
RPMI-8402 T cell acute lymphoblastic leukemia −− − − − − −
RS4;11 B cell precursor leukemia −−−− − −
RS-5 Sacromatoid mesothelioma −−−− − −
RT-112 Urinary bladder carcinoma −− − − − − −
RT-4 Urinary bladder carcinoma −− − − − − −
RVH-421 Melanoma −− − − − − −
S-117 Thyroid sarcoma −− − − − − −
SAOS-2 Osteogenic carcinoma −− − − − − −
SBC-2 Cervix carcinoma (subclone of HELA) −− − − − − −
SBC-7 Cervix carcinoma (subclone of HELA) −− − − − − −
SC-1 B cell lymphoma −−−− − −
SCC-25 Squamous cell carcinoma −−−− −
SCC-4 Squamous cell carcinoma −−−− −16 Journal of Biomedicine and Biotechnology
Table 3: Continued.
Cell line Zelltyp RT-ELISA HCV EBV HBV HIV HTLV SMRV
SCLC-21H Small cell lung carcinoma −− − − − − −
SCLC-22H Small cell lung carcinoma −− − − − − −
SD-1 B lymphoblastoid cells −− + −− − −
SEM B cell precursor leukemia −−−− − −
SET-2 Essential thromobocythemia −−−− − −
SH-2 Acute myeloid leukemia −−−− − −
SHI-1 Acute myeloid leukemia −−−− − −
SH-SY5Y Neuroblastoma −− − − − − −
SIG-M5 Acute monocytic leukemia −−−− − −
SIMA Neuroblastoma −− − − − − −
SISO Cervix carcinoma −− − − − − −
SK-ES-1 Ewing’s sarcoma −−−− − −
SK-HEP-1 Liver adenocarcinoma −− − − − − −
SKM-1 Acute myeloid leukemia −−−− − −
SK-MEL-1 Melanoma −− − − − − −
SK-MEL-3 Melanoma −− − − − − −
SK-MEL-30 Melanoma −− − − − − −
SK-MES-1 Squamous lung carcinoma −− − − − −
SK-MM-2 Multiple Myeloma −− − − − − −
SK-N-BE(2) Neuroblastoma −−−− − −
SK-N-MC Neuroblastoma −− − − − − −
SKW-3 T cell leukemia −− − − − −
SNB-19 Glioblastoma −− − − − − −
SPI-801 Chronic myeloid leukemia (K-562 subclone) −− − − − − −
SPI-802 Chronic myeloid leukemia (K-562 subclone) −− − − − − −
SR-786 Anaplastic large T cell lymphoma −− − − − − −
SU-DHL-1 Anaplastic large cell lymphoma −− − − − − −
SU-DHL-10 B cell lymphoma −−−− − −
SU-DHL-16 B cell lymphoma −−−− − −
SU-DHL-4 B cell lymphoma −−−− − −
SU-DHL-5 B cell lymphoma −−−− − −
SU-DHL-6 B cell lymphoma −−−− − −
SU-DHL-8 B cell lymphoma −−−− − −
SUP-B15 B cell precursor leukemia −− − − − − −
SUP-HD1 Hodgkin lymphoma −−−− − −
SUP-M2 Anaplastic large cell lymphoma −−−− − −
SUP-T1 T cell lymphoma −− − − − − −
SUP-T11 T cell leukemia −−−− − −
SW-1710 Urinary bladder carcinoma −− − − − − −
SW-403 Colon adenocarcinoma −− − − − − −
SW-480 Colon adenocarcinoma −− − − − − −
SW-948 Colon adenocarcinoma −− − − − − −
T2 Human-human somatic cell hybrid − + −− −
T-24 Bladder carcinoma −− − − − − −
TALL-1 T cell leukemia −−−− − −
TANOUE B cell precursor leukemia −− − − − − −
TC-71 Ewing’s sarcoma −−−− − −
TCC-SUP Bladder carcinoma −− − − − − −
TE-671 Rhabdomyosarcoma −− − − − − −
TF-1 Erythroleukemia −− − − − − −
TFK-1 Bile duct carcinoma −− − − − − −
THP-1 Acute monocytic leukemia −− − − − − −
TMM Chronic myeloid leukemia −− + −− − −
TOM-1 B cell precursor leukemia −−−− − −
TT2609-C02 Follicular thyroid carcinoma −−−− −Journal of Biomedicine and Biotechnology 17
Table 3: Continued.
C e l l l i n e Z e l l t y p R T - E L I S AH C VE B VH B VH I VH T L VS M R V
U-138-MG Glioblastoma −− − − − − −
U-2197 Malignant ﬁbrous histiosarcoma −− − − − − −
U-266 Myeloma −− − − − − −
U-2932 B cell lymphoma −−−− − −
U-2940 B cell lymphoma −−−− − −
U-2973 B cell lymphoma −−−− − −
U-698-M B cell lymphoma −− − − − − −
U-937 Hystiocytic lymphoma −− − − − − −
U-H01 Hodgkin lymphoma −−−− − −
ULA B cell lymphoma −−−− − −
UT-7 Acute myeloid leukemia −− − − − − −
VA-ES-BJ Epithelioid sarcoma −− − − − − −
VAL B cell l − + −− − −
VM-CUB1 Bladder carcinoma −− − − − − −
WERI-RB-1 Retinoblastoma −− − − − − −
WSU-DLCL2 B cell lymphoma −−−− − −
WSU-FSCCL B cell lymphoma −−−− − −
WSU-NHL B cell lymphoma −− − − − − −
Y-79 Retinoblastoma −− − − − − −
YAPC Pancreatic carcinoma −− − − − − −
YT T cell/natural killer cell leukemia −− + −− − −
B95-8∗ Lymphocytes −− + −− − −
COS-1∗ Kidney −− − − − − −
COS-7∗ Kidney −− − − − − −
VERO-B4∗ Kidney −− − − − − −
∗: Monkey cell lines; −:n e g a t i v e ;+(bold): positive.
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Figure 2 :D e t e c t i o no fZ E B R Ap r o t e i ni nE B V
+ cell lines. Western
blot analysis with antibodies raised against ZEBRA shows that
ZEBRA can be induced in the cell line HC-1 and that the cell
line BD-215 can be stimulated to increase the expression of the
immediate early protein. Expression in ARH-77 could not be
induced by TPA during 72hours. TPA-stimulated B95-8 was used
as control for the expression of ZEBRA.
byinterphaseFISH.Theanalysisshowedthattheviralloadof
the nonproducing cells within a culture was heterogeneous.
Some cells had high EBV loads, whereas other cells of the
same cell culture showed low or even no viral load. For
example, the cell line DOHH-2 contains only a few cells
with several EBV episomes, whereas in most of the cells
EBV DNA was completely absent (Figure 4(b)). Any cross-
contamination of the cell line was excluded by DNA typing
(data not shown). The heterogeneity of EBV load within a
cell culture population and the ﬁnding that only a small
fraction of cells can be stimulated to enter the lytic phase
implies that speciﬁc cellular factors regulate the propagation
of episomes in the nuclei and the permissivity of the cells
related to EBV. Phosphorylation or methylation of EBV
speciﬁc proteins or epigenetic events like DNA methylation
or histone deacetylation might contribute to the cell speciﬁc
regulation [39].
Linear EBV DNA was detected in a number of cell lines
(Table 2).TheexpressionoflinearEBVgenomeDNAdidnot
correspond to the expression of BZLF1 protein. Although all
BZLF1 positive cell lines produced high levels of linear EBV
DNA, many more BZLF1 negative cell lines also expressed
signiﬁcant levels of linear EBV genomes. This indicates that
the lytic status of the EBV infection is not essential for the
production of linear EBV genomes. The intensities of the
linear EBV DNA bands did not correlate to the intensities
of the episomes. For example, the cell line IM-9 displayed
a very strong episomal DNA signal, whereas no linear DNA
was detectable in untreated cells and very low amounts were
seen in TPA/Na-butyrate treated cells (Figure 5). On the
other hand, cell line YT showed a strong band for linear
DNA, but a weak band for the episomal DNA. The number
of episomes per cell was not aﬀected by the stimulation
with TPA/Na-butyrate, whereas the amount of linear DNA
increased with the addition of TPA in those cell lines which
can be stimulated with the phorbol ester.18 Journal of Biomedicine and Biotechnology
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Figure 3: Detection of circular and linear EBV DNA in cell lines
by in situ lysing gel analysis. 106 cells were resuspended in a
loading buﬀer containing RNase A and loaded into a well of a
0.8% agarose-TBE lysing gel containing SDS and proteinase K.
After electrophoresis the separated DNA was blotted onto nylon
ﬁlters and the DNA was hybridized with
32P labeled EBV cosmid
cM-SalI-A. The upper bands on the autoradiograph constitute the
episomal DNA, whereas the lower bands constitute the linear EBV-
DNAwhichispackedintotheactivevirusesduringvirusformation.
EBV genoms integrated into the chromosomes of the cells do not
enter the gel. Controls include B95-8 as EBV-positive and PLT-21
as EBV-negative cell lines. Episomal EBV DNA can be detected in
all EBV positive cell lines. The amount of linear EBV-DNA is highly
diverse or not present (IM-9, JVM-13) and does not correlate with
the amount of episomal DNA.
Cross-contamination is a serious problem in cell cul-
ture and causes mycoplasma infection and cell line cross-
contamination. To ﬁnd out whether a transfer of EBV
from one cell culture to another can be demonstrated, we
investigatedtheclonalityoftheEBVgenomes.Weperformed
Southern blot analysis with genomic DNA of the EBV-
PCR positive cell lines digested with the restriction enzyme
XhoI. Applying EBV cosmids covering almost the whole EBV
genome [15] each cell line displayed a unique EBV genotype.
The most striking diﬀerences occurred in the lengths of the
terminal repeat (TR) regions which reﬂect the numbers of
repetitive exons. The other parts of the genome covered by
the cosmids (ca. 83% of the B95-8 EBV sequence) showed
also a high variability. Several diﬀerent patterns can be
identiﬁed per cosmid probe and the combination of several
cosmidprobesrevealedahighnumberofdiﬀerentgenotypes
(Figure 6). Even the cell lines which were described to be
establishedwithEBVparticlesoftheB95-8celllinedisplayed
diﬀerences in the lenght of the TR regions of the EBV
genotypes. The JVM cell lines were all established using EBV
and TPA [32]. Nevertheless, the cell lines display diﬀerent
patterns concerning the TR region and a few additional
bands within the EBV genome. The EHEB cell line was also
described to be transformed by B95-8 EBV viruses [9]. The
EHEB cell line displays distinct bands in the XhoI-digested
(a)
(b)
Figure 4: Interphase FISH assay for the demonstration of EBV
in cell lines. Hybridization was performed with EBV cosmid cM-
SalI-A labeled with Spectrum Green by nick-translation. Nuclei
were stained with DAPI. (a) Nuclei of cell line BONNA-12 contains
heterogeneous numbers of EBV copies. (b) Cell line DOHH-2
displays only few cells contaminated with EBV.
EBV DNA diﬀerent from those found in the JVM cell lines.
Nevertheless, the bands of the B95-8 EBV-transformed cell
lines detected in the Southern blots are all more or less
prominently represented within the pattern of the B95-8 cell
line. From these results, we conclude that the B95-8 cell
line harbors diﬀerent genotypes of EBV with the ability to
transform other cells.
Taken together, the various patterns of digested EBV
indicate that the infections with EB viruses originated from
the patient or from the transforming viruses, but not from
dissemination during cell culturing. Although mycoplasma
and cross contaminants are mainly introduced into cell
cultures by inadequate cell culture techniques, this does not
seem to be the case with regard to the distribution of EBV
in cell cultures. The low number of unintended intercell line
contamination by EBV might be based on the low number
of cell lines which produce actively EBV. Additionally, only a
limited number of cell lines are susceptible to the infection
with EBV at all.
3.2. Detection of HBV. HBV particles contain a circular,
partially double-stranded DNA of 3.2 kb. HBV can be grown
i np r i m a r yc e l lc u l t u r e so fn o r m a la d u l to rf e t a lh u m a n
hepatocytes, but propagation was not yet shown in untreatedJournal of Biomedicine and Biotechnology 19
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Figure 5: Detection of circular and linear EBV DNA in untreated
and TPA-treated cell lines by in situ lysing gel analysis. Cells were
stimulated for 72hours with 10
−7 M TPA and 0.3M Na-butyrate.
All conditions were as described in the legend for Figure 3.T h e
cell lines B95-8 and YT can be eﬃc i e n t l ys t i m u l a t e dt op r o d u c e
high amounts of linear EBV genomes, whereas BD-215 cannot be
triggered to produce more linear DNA and IM-9 is not induced to
produce linear DNA by TPA/Na-butyrate.
continuous cell lines. Production of HBV particles can be
achieved to date only by transfection of hepatocyte cell
lines with plasmids containing HBV genomes [47]. In cell
lines, the HBV genome is integrated into the eukaryotic
chromosomes with variable copy numbers as shown for
several cell lines, for example, HCCM, HEP-3B, HUH-1,
HUH-4, and PLC/PRF/5 [48]. Except for HCCM, all these
cell lines express the hepatitis B surface antigen HBsAg.
The HBV PCR assay used here ampliﬁed conserved
sequences of the core region of HBV and was evaluated using
HBV reference plasma No 1 (subtype ad) and No 2 (subtype
ay) which were established in cooperation with the European
Study Group on Viral Hepatitis (EUROHEP). In order to
determine the detection limit, we performed a dilution series
of the HBV particles in conditioned cell culture supernatant
of an HBV negative cell line. Subsequently, the HBV particles
were recollected by ultracentrifugation, DNA was extracted,
and the PCR reaction was performed as described in the
methods section. The sensitivity was determined as ca. 50
particles per PCR reaction. This corresponds to ca. 250 HBV
particles per mL cell culture supernatant (data not shown).
We screened 465 primate cell lines (Table 3)b yp e r -
forming PCR assays for the detection of active HBV with
DNA extractions of the cell culture supernatants and found
no HBV+ cell lines. The HEP-3B cell line was described
to carry the HBV genome integrated into the eukaryotic
chromosomes[49],butthePCRmethodweapplieddetected
the contamination neither in the supernatant nor using
genomic DNA of the cell line. Su et al. [49] investigated the
HBV genome and the integration site within the eukaryotic
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Figure 6: Southern blot analysis of diﬀerent cell lines. Fifteen μg
genomic DNA of the cell lines were digested with XhoI and the
restriction fragments were separated on an agarose gel. The DNA
was blotted onto nylon ﬁlters and the blot was hybridized to a ca.
900bp
32P-labeled PCR product spanning the 5 -region of EBV
(LMP fragment 1). A rehybridization of the same blot with a probe
for the 3 -region of the linear EBV genome after stripping revealed
the same bands, indicating that circular EBV DNA is detected.
genome. They determined a ca. 2.3kb fragment originating
from HBV in the HEP-3B cell line and the integration
was associated with a chromosomal translocation of the
chromosomes 4 and 13. The HBV core region is deleted in
the HEP-3B cell line and was thus not detected by the PCR
analysis. We conﬁrmed the presence of the HBV fragment in
the HEP-3B cell line by Southern blot analysis (Figure 7)o n
genomicDNAandbyPCRampliﬁcationofthecodingregion
of the HBsAg.
In HEP-G2 and SK-HEP-1, a hepatocellular carcinoma,
and a liver adenocarcinoma cell line, respectively, we did not
detect HBV sequences by PCR or Southern blot analysis.
Both cell lines are not contaminated with HBV.
3.3.DetectionofHCV. HCVinfectionsarewidelydistributed
all over the world and are associated with chronic hep-
atitis. Until its identiﬁcation in 1988, the virus was the
predominant causative of transfusion-associated hepatitis.
Similarly to HBV, until now HCV cannot be propagated in
unmanipulated continuous human cell lines.
HCV is a 9.6kb linear positive-stranded RNA virus and
can be detected by reverse transcriptase PCR (RT-PCR). The
5 -UTR is the most conserved part of the virus genome
and commonly used for the ampliﬁcation by RT-PCR. We
extracted total RNA from the cell lines and the integrity
of the RNA was evaluated by demonstration of the rRNA
bands on an ethidium bromide stained gel. The subsequent
RT reaction was veriﬁed by a PCR reaction amplifying the
ubiquitously expressed ABL transcript. This PCR allows (i)
to demonstrate the sensitivity of the RT-PCR, because ABL
is only moderately transcribed in human cells, and (ii) to
distinguish between the cDNA and residual genomic DNA,
because the primers are located in two diﬀerent exons of the
ABL gene. Due to the lack of availability of HCV positive20 Journal of Biomedicine and Biotechnology
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Figure 7:SouthernblotanalysisforthedetectionofHBVsequences
in human cell lines. The cell lines HEP-3B, HEP-G2, and SK-HEP-
1 are cell lines established from human hepatocellular carcinomas.
The ARH-77 is a human hematopoietic cell line and serves as
a negative control. Genomic DNA was digested with BamHI,
separated on an agarose gel, blotted and hybridized with a
32P
labeled PCR fragment covering the Hepatitis B surface antigen
coding region. The hepatocellular carcinoma cell lines SK-HEP-1
and HEP-G2 display no HBV sequences, whereas HEP-3B shows
a hybridization signal at about 1.6kb originating from HBV
sequences integrated into the cellular genome.
cell lines, we used a plasmid containing the 5 - U T Ro fH C V
as positive control and produced an internal control DNA
to verify each PCR reaction. The sensitivity of the assay was
determined as 10–100 copies per PCR reaction.
We investigated 465 cell lines (Table 3) applying RT-PCR
for the conserved 5 -UTR of the HCV genome. None of the
cell lines were positive for HCV. This result supports the
observation that HCV cannot be propagated in human or
other primate cell lines.
3.4.DetectionofHIV-1andHTLV-Iand-II. Theretroviruses
HIV-1 and HTLV-I and II infect human T cells and are
involved in the development of AIDS and the adult T-cell
leukemia, respectively. The retroviruses contain two RNA
molecules which are reverse transcribed into DNA and
integrated as proviruses into the host genome. HIV and
HTLV can be propagated in continuous cell lines and a
number of cell lines were described as being latently infected
or actively producing viruses.
PCR assays were established to detect latent infections in
terms of proviruses of HIV-1 and HTLV-I and -II in the cell
lines. The sensitivity of the PCR assays was determined as
about 20 copies per reaction. DNA of the MT-1 cell line was
used as positive control for the HTLV-PCR and a plasmid
containing the HIV-1 gag and pol regions as positive control
for HIV-1.
In total 465 primate cell lines of the cell bank (Table 3)
were analyzed by PCR for the presence of those retroviruses
and none of the cell lines were found to be infected with
HIV or HTLV sequences. Furthermore, 293 of these cell
lines were tested for the activity of RT. Only the cell line
KASUMI-1 was found to be positive. The activity of 5mL
conditioned KASUMI-1 cell culture supernatant showed an
RT activity that was equivalent to approximately 2ng of
HIV-1 RT (speciﬁc activity > 5U/μg). For comparison, 5mL
supernatant of the ovine cell line FLK-BLV, which is infected
with the bovine leukemia virus, shows an activity equivalent
to ca. 10ng of HIV-1 RT. The cause of the RT activity could
not be determined. But PCR analyses excluded the presence
of HIV-1, HTLV-I/-II, and SMRV.
3.5. Detection of SMRV. SMRV was ﬁrst isolated from the
lungcellcultureofasquirrelmonkeyaftercocultivationwith
other cell cultures [50]. The endogenous virus belongs to the
beta-retroviruses and exhibits Mg-dependent RT. SMRV is
not pathogenic to its natural host and pathogenicity was not
described for human or other species. The xenotropic virus
was shown to be expressed in diﬀerent cell lines of canine,
man, chimpanze, rhesus monkey, and mink origin. Natural
or alternate hosts other than squirrel monkey were not yet
identiﬁed.
Already in 1974 retroviral particles were detected in the
human hematopoietic cell line RPMI-8226 which were later
identiﬁed as SMRV [6, 51]. Oda et al. reported the detection
of retroviruses in the human lymphoblastoid cell line HLB
which turned out to be SMRV [52, 53]. Middleton et al.
reported the insertion of SMRV sequences in the genome
of the human Burkitt lymphoma cell line Namalwa [54].
The subclone Namalwa.IPN/45 contains two partial SMRV
copies integrated into the cMYC gene locus and 10 further
copies integrated at diﬀerent sites of the genome of the
cell line. They also found SMRV sequences in the EBV
producing monkey cell line B95-8 and demonstrated that
SMRV was transmitted when EBV particles from the B95-
8 cell line were used to establish a B lymphoblastoid cell
line. SMRV sequences were also detected in interferon-α
preparations which were produced using the Namalwa cell
line [55]. Retroviruses generally insert themselves into the
genome of the host cell. As seen in the cell line Namalwa,
the insertion can aﬀect not only the transcription activity
of cellular oncogenes but also tumor suppressor genes or
other regulatory genes. Beside the possibility of altering the
cellular characteristics, this leads also to a certain, at least
theoretically, possible pathogenicity of retrovirus infections
per se; hence the release of those viruses—especially with a
v e r yb r o a dh o s tc e l ls p e c t r u ms u c ha sx e n o t r o p i cS M R V —
shouldbeminimized.Moreover,apotentialriskoccurswhen
cells infected with retroviruses are subjected to retroviral-
mediated gene transfer. A recombination of the replication
deﬁcientretrovirusandthewildtyperetroviralgeneticinfor-
mation might lead to a complementation of the replication
defect and to replication-competent retroviruses [56].
We investigated 430 human and 4 monkey cell lines
(Table 3) for the occurrence of SMRV DNA sequences in theJournal of Biomedicine and Biotechnology 21
genome. Six cell lines were found to be positive for SMRV:
ﬁve Namalwa subclones (Namalwa, Namalwa.CSN/70,
Namalwa.IPN/45, Namalwa.KN2, Namalwa.PNT) and the
human lymphoblastoid cell line LCL-HO. Middleton et al.
investigated Namalwa cell lines from diﬀerent laboratories
and found no SMRV-free Nalmalwa cell cultures [54]. Our
subclones were received from two diﬀerent laboratories in
Japan and Scotland. Presumably, all NAMALWA cell lines
are contaminated with SMRV and no SMRV-free cell line
is available. The LCL-HO cell line is a lymphoblastoid cell
line which was established by transformation of a patients
primary B cells with EBV. We suspect that SMRV was
transmitted by the use of EBV from an SMRV infected
B95-8 cell line. Other LCLs which were transformed with
EBV from B95-8 showed no SMRV contamination. This
indicates that only some of the B95-8 subclones contain
SMRV.
T h ec e l ll i n e sw e r er e c e i v e df r o md i ﬀerent sources
worldwide. The low infection rate of the cell lines indicates
that SMRV is not transmitted to other cell cultures com-
parable to the distribution of mycoplasma or cell line cross
contaminations, although many diﬀerent cell types were
shown to be susceptible to an infection. Nevertheless, the
transmission of these xenotropic viruses during cultivation
and handling of infected cell cultures to other cell lines
cannot be excluded.
4. Conclusions
In summary, we showed that human and other primate
cell lines directly obtained from a biological resource center
do not carry high-risk viral contaminants and thus do not
represent safety risks for cell culturists. The PCR assays
provide a robust, fast, inexpensive, sensitive, and reliable
method for routine screening. The additional feature of
incorporating an internal control in each assay reduces
the possibility of false-negative data. Importantly, unlike
mycoplasma and other bacterial infections and cell line
cross contamination, viruses are not disseminated among
cell lines due to poor cell culture technique. Only a minor
part of the EBV+ cell lines produces active viruses or
can be stimulated to produce them. Detection of BZLF1
protein by Western blot, TR sequences by Southern blot,
and interphase FISH can be applied to recognize cell lines
producing active EBV particles and to assign a cell culture
to a legal risk group. Newly established cell lines should
be tested for EBV-infections to detect EBV-transformed B-
cells giving rise to B-LCLs. On the other hand, the use of
E B Vf r o ma nS M R V + B95-8 cell line to establish B-LCLs
might carry the risk of coinfecting the reccipient cells with
SMRV.
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